title: MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
source: Yahoo
date: 2025-10-07
url: https://finnhub.io/api/news?id=20a3cb356afcc9fd863d3934668c2936f37e68ca847f6d5de4151b3d5d503c85
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
